


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of formula I:



wherein:

R₁ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, pyridinyl, -CH₂-pyridinyl, phenyl or benzyl, the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups ~~may be~~ are optionally substituted by from 1 to 3 groups selected from the group ~~chemistry~~ consisting of halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OH, -NH₂, and -NO₂;

R₂ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl;


R₃ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, -NH₂, or -NO₂;

R₄ is phenyl, benzyl, benzyloxy, pyridinyl, or -CH₂-pyridinyl, wherein the rings of these groups ~~may be~~ are optionally substituted by 1 to 3 groups selected from the group ~~chemistry~~ consisting of halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OH, -NH₂, and -NO₂;

R₈ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, ~~or~~ C₁-C₃ perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl; and


R₉ is hydrogen, C₁-C₆ alkyl, C₃-C₆ branched alkyl, 4-hydroxybenzyl, 3-indolylmethylene, 4-imidazolylmethylene, CH₃SCH₂CH₂-, H₂NC(=O)CH₂-, H₂NC(=O)CH₂CH₂-, HO₂CCH₂-, HO₂CCH₂CH₂-, H₂NCH₂CH₂CH₂CH₂-, H₂NC(=NH)NHCH₂CH₂CH₂-, or taken together with R₈, -CH₂CH₂CH₂-; or a pharmaceutically acceptable salt or ester form thereof.

2. (Original) A compound of Claim 1 having the formulas:



(II)


or



(III)


wherein R₁, R₂, R₃, R₄, R₈ and R₉ are as defined in Claim 1, or a pharmaceutically acceptable salt or ester form thereof.

3. (Currently amended) A compound of Claim 1 having the formulas:



(IV)

or



(V)

wherein:

R₁ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or benzyl, wherein the rings of the cycloalkyl and benzyl groups ~~may be~~ are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, preferably -O-CF₃, C₁-C₃ alkoxy, -OH, -NH₂, or -NO₂;

R₂ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl;

R₃ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, -NH₂, or -NO₂;

R₅, R₆ and R₇ are each independently hydrogen, halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OH, -NH₂, or -NO₂;

R₈ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl;

R₉ is hydrogen, C₁-C₆ alkyl, C₃-C₆ branched alkyl, C₄-C₆ hydroxyalkyl, 4-hydroxybenzyl, 3-indolylmethylene, 4-imidazolylmethylene, HSCH₂-, CH₃SCH₂CH₂-, H₂NC(=O)CH₂-, H₂NC(=O)CH₂CH₂-, HO₂CCH₂-, HO₂CCH₂CH₂-, H₂NCH₂CH₂CH₂CH₂-, H₂NC(=NH)NHCH₂CH₂CH₂-, or taken together with R₈, -CH₂CH₂CH₂-;


or a pharmaceutically acceptable salt or ester form thereof.

4. (Original) The compound of Claim 1 which is {[1-(4-*tert*-butylbenzyl)-5-(3-methylphenyl)-1*H*-indol-3-yl](oxo)acetyl]amino}acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

5. (Original) The compound of Claim 1 which is 2-[(2-{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1*H*-indol-3-yl}-2-oxoacetyl)amino]acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

6. (Original) The compound of Claim 1 which is 2-[(2-{1-Benzyl-5-[3-(trifluoromethoxy)phenyl]-1*H*-indol-3-yl}-2-oxoacetyl)(methyl)amino]acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

7. (Currently amended) A method of inhibiting plasminogen activator inhibitor-1 in a mammal for treatment of thrombosis or fibrinolytic impairment in a mammal wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion, comprising administering to a mammal in need thereof a pharmaceutically effective amount of compound of formula:



wherein:

R₁ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, pyridinyl, -CH₂-pyridinyl, phenyl or benzyl, the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups ~~may be~~ are optionally substituted by from 1 to 3 groups selected from the group ~~chemistry~~ consisting of halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OH, -NH₂, and -NO₂;

R₂ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl;

R₃ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, -NH₂, or -NO₂;

R₄ is phenyl, benzyl, benzyloxy, pyridinyl, or -CH₂-pyridinyl, wherein the rings of these groups ~~may be~~ are optionally substituted by 1 to 3 groups selected from the group ~~chemistry consisting~~ of halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OH, -NH₂, and -NO₂;

R₈ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, ~~or~~ C₁-C₃ perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl; and

R₉ is hydrogen, C₁-C₆ alkyl, C₃-C₆ branched alkyl, C₁-C₆ hydroxyalkyl, 4-hydroxybenzyl, 3-indolylmethylene, 4-imidazolylmethylene, HSCH₂-, CH₃SCH₂CH₂-, H₂NC(=O)CH₂-, H₂NC(=O)CH₂CH₂-, HO₂CCH₂-, HO₂CCH₂CH₂-, H₂NCH₂CH₂CH₂CH₂-, H₂NC(=NH)NHCH₂CH₂CH₂-, or taken together with R₈, -CH₂CH₂CH₂-;

or a pharmaceutically acceptable salt or ester form thereof.

8. (Original) A pharmaceutical composition comprising pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or ester form thereof, and a pharmaceutically acceptable excipient or carrier.

9-12. (Canceled)

13. (Currently amended) The method of claim 7 for the treatment of thrombosis or fibrinolytic impairment wherein the thrombosis or fibrinolytic impairment is associated with deep vein thrombosis in a the mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

14-21. (Canceled)